Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Business Wire India Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the…